Testing a new memory assessment in people with memory disorders
Tests a new memory assessment tool in people with memory disorders, aged 50 and older.
Key facts
- Who runs it
- University Hospital, Tours
- Where
- Tours, FranceSee the site
- Trial code
- Registry title
- Development, Standardisation and Standardisation Project for a New Memory Assessment
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 22 Nov 2024
- Expected to end
- Nov 2028
- Type of study
- Observational
- Treatments tested
- New memory assessment
- Record updated
- 30 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 or older with an amnesic mild cognitive impairment profile (memory-type problems) who are getting a new memory test.
- Age
- 50 years or older
- Sex
- All sexes can join.
- Disease stage
- Amnesic MCI profile (mild cognitive impairment with memory loss), seen at the first medical consultation before the test was prescribed.
Main reasons for not taking part
- Severe hearing and/or vision problems that do not fit with the memory assessment
- Patient under guardianship, curatorship or family guardianship
- Opposition to data processing
- Cannot understand well enough, as judged by the assessor
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥ 50 years
- Ability to understand judged sufficient by the assessor
- Amnesic MCI profile (Petersen, 2003) during the 1st medical consultation prior to the assessment being prescribed
Who cannot take part
- Severe auditory and/or visual sensory impairment not compatible with neuropsychological assessment
- Judged fit to take the test by the assessor
- Patient under guardianship, curatorship or family guardianship
- Opposition to data processing
Where in France
- University hospitalTours, FranceContact: Alix LAUNAYTaking people
About the trial
What the trial wants to find out
Episodic memory (EM) is a neuropsychological marker of Alzheimer's disease (AD) (Thomas-Anterion, 2006). Current tests for its assessment do not take into account the identity and emotional aspects of memory (Van der Linden et al., 2018). However, there are models that integrate links with identity, self-awareness and experience. Pause et al. (2013) propose criteria to create ecological tools, including consideration of the emotional valence of memories and the spatio-temporal context of acquisition. In line with these criteria, we have developed a new tool: the NEM (New evaluation of Episodic Memory). Preliminary studies show different response profiles on the NEM among patients (Launay et al., 2023). We now want to evaluate the relevance of this tool in the differential diagnosis of AD.
The group in the trial
- group intervention
patients benefiting from the new memory assessment
Treatment: New memory assessment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Development, Standardisation and Standardisation Project for a New Memory Assessment
- Plain-language title
- Testing a new memory assessment in people with memory disordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 April 2026